Brokerages Set Climb Bio, Inc. (NASDAQ:CLYM) Price Target at $9.20

Climb Bio, Inc. (NASDAQ:CLYM) has been given an average recommendation of “Buy” by the nine research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.20.

A number of analysts recently issued reports on CLYM shares. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a research report on Thursday, October 16th. Baird R W raised shares of Climb Bio to a “strong-buy” rating in a research note on Friday, August 15th. HC Wainwright began coverage on shares of Climb Bio in a research note on Monday, October 13th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th.

Institutional Investors Weigh In On Climb Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Peapod Lane Capital LLC grew its position in Climb Bio by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company’s stock valued at $1,129,000 after acquiring an additional 6,199 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Climb Bio by 11.9% during the third quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock worth $268,000 after purchasing an additional 14,210 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Climb Bio during the third quarter worth about $29,000. AQR Capital Management LLC purchased a new position in shares of Climb Bio in the first quarter valued at approximately $27,000. Finally, UBS Group AG grew its holdings in shares of Climb Bio by 6.0% in the third quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after purchasing an additional 22,922 shares in the last quarter. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Stock Performance

CLYM stock opened at $1.80 on Friday. The firm has a market cap of $122.72 million, a PE ratio of -2.37 and a beta of -0.06. The firm’s 50 day moving average price is $1.98 and its 200-day moving average price is $1.72. Climb Bio has a one year low of $1.05 and a one year high of $3.30.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Equities research analysts predict that Climb Bio will post -1.57 EPS for the current fiscal year.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.